Mutations in the gene encoding hepatocyte nuclear factor-4α (HNF-4α) result in maturity-onset diabetes of the young (MODY). To determine the contribution of HNF-4α to the maintenance of glucose homeostasis by the β cell in vivo, we derived a conditional knockout of HNF-4α using the Cre-loxP system. Surprisingly, deletion of HNF-4α in β cells resulted in hyperinsulinemia in fasted and fed mice but paradoxically also in impaired glucose tolerance. Islet perifusion and calcium-imaging studies showed abnormal responses of the mutant β cells to stimulation by glucose and sulfonylureas. These phenotypes can be explained in part by a 60% reduction in expression of the potassium channel subunit Kir6.2. We demonstrate using cotransfection assays that the Kir6.2 gene is a transcriptional target of HNF-4α. Our data provide genetic evidence that HNF-4α is required in the pancreatic β cell for regulation of the pathway of insulin secretion dependent on the ATP-dependent potassium channel.
The MODY1 gene HNF-4α regulates selected genes involved in insulin secretion

Rana K. Gupta,1,2 Marko Z. Vatamaniuk,1,2 Catherine S. Lee,1,2 Reed C. Flaschen,1,2 James T. Fulmer,1,2 Franz M. Matschinsky,2,3 Stephen A. Duncan,4 and Klaus H. Kaestner1,2

1Department of Genetics, 2Institute for Diabetes, Obesity, and Metabolism, and 3Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. 4Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Mutations in the gene encoding hepatocyte nuclear factor-4α (HNF-4α) result in maturity-onset diabetes of the young (MODY). To determine the contribution of HNF-4α to the maintenance of glucose homeostasis by the β cell in vivo, we derived a conditional knockout of HNF-4α using the Cre-loxP system. Surprisingly, deletion of HNF-4α in β cells resulted in hyperinsulinemia in fasted and fed mice but paradoxically also in impaired glucose tolerance. Islet perfusion and calcium-imaging studies showed abnormal responses of the mutant β cells to stimulation by glucose and sulfonylureas. These phenotypes can be explained in part by a 60% reduction in expression of the potassium channel subunit Kir6.2. We demonstrate using cotransfection assays that the Kir6.2 gene is a transcriptional target of HNF-4α. Our data provide genetic evidence that HNF-4α is required in the pancreatic β cell for regulation of the pathway of insulin secretion dependent on the ATP-dependent potassium channel.

Introduction

Maturity-onset diabetes of the young (MODY) is a mendelian form of type 2 diabetes characterized by an autosomal dominant mode of inheritance, early onset, and impaired glucose-stimulated insulin secretion. MODY can result from mutations in at least 6 different genes. One of these encodes the glycolytic enzyme glucokinase (MODY2), which is an important glucose sensor, while all the others encode transcription factors: hepatocyte nuclear factor-4α (HNF-4α) (MODY1); HNF-1α (MODY3); insulin promoter factor 1 (IPF1/pancreatic duodenal homeobox 1 [Pdx-1]) (MODY4); HNF-1β (MODY5); and neurogenic differentiation factor 1 (NeuroD1) (MODY6) (1). Genetic and biochemical studies have revealed that many of these transcription factors participate in a transcriptional regulatory network in both the liver and pancreas.

A hierarchy among MODY genes has been derived from the molecular analysis of MODY, as mutations in both the gene encoding HNF-4α (MODY1) and the binding site for the protein HNF-4α in the HNF-1α promoter cause diabetes (2, 3). In addition, more recent studies have demonstrated that mutations in the β cell–specific promoter (P2) of HNF-4α in humans are associated with increased risk of type 2 diabetes (4–6). Therefore, it has been proposed that HNF-1α and HNF-4α form a regulatory loop in the adult β cell and that this regulatory loop is essential for β cell function (7, 8). Furthermore, it was hypothesized that haploinsufficiency for either gene can cause a breakdown in the regulatory loop, ultimately resulting in diabetes (9). However, much of the information about the role of HNF-4α in the pancreas so far has been based on expression and biochemical data. For example, when a dominant negative form of HNF-4α was overexpressed in insulinoma cells, several genes involved in glucose metabolism as well as HNF-1α were differentially expressed, suggesting that HNF-4α regulates β cell glucose metabolism through the regulation of HNF-1α and several glycolytic and mitochondrial genes (9, 10). Most recently, Odom and colleagues combined chromatin immunoprecipitation with promoter microarrays to identify over 1000 human promoter elements bound by HNF-4α in pancreatic islets, suggesting that HNF-4α may function to regulate multiple pathways in the β cell (11). Although it has been shown that HNF-4α is required for maintenance of the expression of HNF-1α and important metabolic genes in the liver, it remains unknown whether this relationship holds true in the pancreatic β cell or whether HNF-4α is essential for β cell glucose metabolism in vivo. Understanding the relationship between MODY genes and their specific functional targets in vivo may identify a common mechanism of pathogenesis and lead to a novel approach for improving β cell function.

MODY1 patients fail to secrete insulin adequately in response to glucose challenge (12). This observation, along with other recent biochemical studies, suggests that HNF-4α plays a role in pancreatic development and/or in the regulation of β cell function. However, the exact role of HNF-4α in the maintenance of β cell function has not to our knowledge been determined in vivo until now. Because targeted disruption of HNF-4α in mice results in early death due to defective gastrulation (13, 14), genetic analysis of the function of HNF-4α in the adult pancreas has thus far been precluded. To determine the role of HNF-4α in the β cell and in the maintenance of glucose homeostasis in vivo, as well as its contribution to the molecular etiology of MODY, we have derived a conditional knockout of HNF-4α using the Cre-loxP system. Deletion of HNF-4α in β cells resulted in impaired glucose tolerance but, surprisingly, also in fasting and fed hyperinsulinemia. The data presented here reveal an unpredicted role for HNF-4α in the regulation of the pathway of insulin secretion dependent on the
ATP-dependent potassium channel (K<sub>ATP</sub> channel) and demonstrate that HNF-4α is not required for the maintenance of HNF-1α expression in the adult β cell.

**Results**

**β cell–specific deletion of HNF-4α.** In order to obtain mice lacking HNF-4α in pancreatic β cells, we mated HNF-4α<sup>loxP/loxP</sup> mice to mice containing a transgene with Cre recombinase under control of the rat insulin 2 promoter (Ins.Cre) (15). The resulting HNF-4α<sup>loxP/loxP</sup>; Ins.Cre offspring were then bred to HNF-4α<sup>loxP/loxP</sup> homozygotes to obtain HNF-4α<sup>loxP/loxP</sup>; Ins.Cre mutants and the littermate groups HNF-4α<sup>loxP/loxP</sup>; Ins.Cre and HNF-4α<sup>loxP/loxP</sup>; Ins.Cre. (Figure 1A). HNF-4α<sup>loxP/loxP</sup> mice were born with an expected mendelian distribution and no significant differences in size or appearance were observed at birth or in adult mice (control = 28.6 ± 1.3 grams; mutants = 30.7 ± 1.8 grams; n = 6–8 mice; 5 months of age; P = NS) compared with littermate controls (HNF-4α<sup>loxP/loxP</sup> and HNF-4α<sup>loxP/loxP</sup>.)

To evaluate the specificity and efficiency of Cre-mediated deletion of HNF-4α, we first used PCR analysis of genomic DNA to determine if the floxed exon 2 of the HNF-4α gene was excised in freshly isolated islets of HNF-4α<sup>loxP/loxP</sup>; Ins.Cre and HNF-4α<sup>loxP/loxP</sup> mice (Figure 1B). Primers were designed to amplify a 450-bp product only detectable when the floxed HNF-4α gene was deleted. The PCR analysis indicated that gene ablation occurred in approximately 70% of cells in the islets of HNF-4α<sup>loxP/loxP</sup>; Ins.Cre mice. Concordantly, mRNA levels of HNF-4α in isolated islets of HNF-4α<sup>loxP/loxP</sup>; Ins.Cre mice were reduced by approximately 63% compared with controls (Figure 1C). Given that 30–40% of islet cells are non-β cells that express HNF-4α, this degree of reduction in whole islets suggests deletion in greater than 90% of β cells. We confirmed the β cell specific inactivation of HNF-4α by examining the expression of HNF-4α protein by immunohistochemistry. HNF-4α is normally found in all cell types of the islet and throughout most of the acinar tissue (Figure 1D). Consistent with previous reports of the use of the Ins.Cre-transgenic line, we found that approximately 90% of pancreatic β cells in the HNF-4α<sup>loxP/loxP</sup>; Ins.Cre mice had lost HNF-4α expression by 2–3 weeks after birth, while the expression of HNF-4α was maintained throughout the remainder of the islet as well as in surrounding exocrine tissue (Figure 1E) (15–18). Staining of adjacent sections for insulin and glucagon confirmed the continued presence of HNF-4α protein in β cells, demonstrating the specificity of the Ins.Cre-mediated gene ablation within the pancreas (data not shown).

The Ins.Cre-transgenic mouse used in this study has been reported to excise loxp targets ectopically in the central nervous system. This issue is of potential significance, as the hypothalamus plays an important role in glucose homeostasis. However, this ectopic activity of the Ins.Cre transgene is only relevant if the loxp-flanked gene to be targeted is expressed in the brain. Multiple expression studies of HNF-4α have failed to detect any expression of this gene in the neuroectoderm during development, or in the hypothalamus or other brain regions in the adult mouse, making it extremely unlikely that HNF-4α plays a role in the central nervous system (19, 20). Fasting corticosterone levels, which are controlled by the hypothalamic-pituitary-adrenal axis, in mutant mice are not changed (control, 245 ± 62 ng/ml; mutant, 277 ± 49 ng/ml; n = 5 mice; P = NS), supporting the notion that hypothalamic function is maintained in HNF-4α<sup>loxP/loxP</sup>; Ins.Cre mice. Thus, it is unlikely that any excision of the floxed HNF-4α allele in the brain would contribute to the phenotype of HNF-4α<sup>loxP/loxP</sup>; Ins.Cre mice. In addition, our studies on isolated islets described below demonstrate a specific requirement for HNF-4α in the β cell.

**β cell deletion of HNF-4α results in hyperinsulinemia and impaired glucose tolerance in vivo.** Next we determined the effect of HNF-4α deficiency in the β cell on glucose homeostasis in vivo by measuring fed and fasting blood glucose levels in the HNF-4α<sup>loxP/loxP</sup>; Ins.Cre mice. Compared with controls, HNF-4α mutants exhibited a mild decrease in blood glucose levels in both the fed and fasting states (Figure 2A). To determine if this difference in blood
glucose was a result of changes in circulating levels of insulin and glucagon, we measured plasma levels of these hormones. We found that in both the fed and fasting states, plasma insulin was significantly elevated in the mutants compared with the littermate controls (Figure 2B). In contrast, fasting plasma levels of glucagon were unchanged (Figure 2C). Therefore, the ratio of plasma insulin to plasma glucagon was approximately 70% higher in HNF-4αloxP/loxP; Ins.Cre mice, which accounted for the lower glucose levels observed in these mice (Figure 2D). Together, these results demonstrate that HNF-4α in the β cell contributes to the maintenance of glucose homeostasis.

Suspecting abnormal regulation of insulin secretion in HNF-4α-deficient β cells, we performed glucose tolerance tests on 3- to 5-month-old HNF-4αloxP/loxP; Ins.Cre mice and littermate controls. After glucose injection, the elevation in blood glucose levels was significantly higher in HNF-4α mutants, indicating impaired glucose tolerance in these animals (Figure 2E). As glucose intolerance can result from decreased peripheral insulin sensitivity or impaired glucose stimulated insulin secretion, we measured plasma insulin levels at various time points after glucose challenge. We found that despite a significantly higher basal level of plasma insulin prior to glucose injection (mutant, 0.21 ± 0.02 ng/ml, n = 11; control, 0.14 ± 0.02 ng/ml, n = 11; P < 0.05), plasma insulin levels failed to increase in the mutant mice at the same rate as in controls after injection (Figure 2F). In particular, HNF-4α mutants lacked a robust first-phase insulin secretory response. In order to investigate the possibility that peripheral insulin resistance contributes to the glucose intolerance of HNF-4α mutants, we performed insulin tolerance tests. Both groups of mice showed similar insulin responses (Figure 2G), concordant with the fact that HNF-4α is not deleted in the major insulin-responsive tissues in our model. These results indicate that while HNF-4α mutants have higher basal plasma insulin levels, they fail to secrete sufficient insulin in response to exogenous glucose administration and thus suffer from dysregulated insulin secretion and impaired glucose tolerance.

Loss of HNF-4α in the β cell does not affect islet architecture or β cell mass at 4 months of age. Several mechanisms can account for the dysregulation of insulin secretion in vivo, including changes in islet architecture or β cell mass, defective glucose sensing and metabolism, or a combination of these factors. For example, disruption of HNF-4α in mice results in defective glucose sensing and the failure of isolated islets from these animals to properly respond to glucose (21, 22). More recent studies have shown that heterozygous deletion of Pdx-1 in mice results in a decrease in β cell mass due to an increase in islet apoptosis (23).

To determine the effect of HNF-4α deficiency in the β cell on islet architecture, we performed indirect immunofluorescence using antibodies raised against the pancreatic hormones insulin, glucagon, somatostatin, and pancreatic polypeptide (PP) to label 4 major islet cell types: β cells, α cells, δ cells, and PP cells, respectively. We found that both the control mice (Figure 3, A and C) and HNF-4αloxP/loxP; Ins.Cre mice (Figure 3, B and D) contained all 4 pancreatic islet cell types, with the insulin-producing β cells centrally located within the islet and the less-frequent α cells, δ cells, and PP cells (not shown) located on the periphery. In addition, using point-counting morphometry, we determined the β cell mass in both HNF-4αloxP/loxP; Ins.Cre mice and littermate controls at 4 months of age and found no significant difference between the 2 groups (control, 0.93 ± 0.17 mg, n = 6; mutant, 1.04 ± 0.22 mg, n = 5; P = NS) (Figure 3E). Together, these results indicate that HNF-4α is not required in the β cell for the maintenance of islet architecture or β cell mass at this age, suggesting that the defect in insulin secretion is a consequence of loss of β cell function rather than β cell differentiation.

Diminished first-phase insulin secretion from isolated islets of HNF-4α mutant mice. We performed insulin secretion studies of perifused
Glucose-stimulated insulin secretion from the pancreatic islets of both controls and mutants failed to decrease as rapidly when glucose was stopped (Figure 4D). To determine if other insulin secretagogues can trigger proper calcium influx, we treated islets with the K<sub>ATP</sub> channel blocker glyburide as well as with KCl to fully depolarize the plasma membrane. In control islets, glyburide and KCl treatment resulted in a strong and rapid rise in intracellular calcium (Figure 4C). In contrast, intracellular calcium increased at a slower rate in mutant islets exposed to glyburide, but increased normally in response to KCl (Figure 4D).

HNF-4<alpha> is required for potassium channel subunit Kir6.2 expression in the pancreatic beta cells. The observation that both KCl-induced calcium influx and insulin release as well as glucose metabolism in mutant mice are indistinguishable from those of controls suggested a defect downstream of glucose metabolism but upstream of the voltage-gated calcium channels. The diminished response to glyburide pointed to a defect in K<sub>ATP</sub>-channel function. Therefore, we examined mRNA levels of the 2 essential subunits of the channel, SUR1 and Kir6.2. While no statistically significant differences were observed in SUR1 subunit expression, mRNA and protein levels of Kir6.2 were downregulated by 40% and 60%, respectively, in the islets of HNF-4<alpha>(loxP/loxP); Ins.Cre mice (Figure 5, D and F). Given that Kir6.2 and SUR1 are expressed in alpha cells as well as beta cells and that the Ins.Cre transgene mediates HNF-4<alpha> deletion only in approximately 85% of beta cells, the actual reduction in Kir6.2 expression in HNF-4<alpha>-deficient beta cells is likely to be greater than 60%. This reduced expression of Kir6.2 provides a possible molecular link between the loss of HNF-4<alpha> in the beta cell and the dysregulation of insulin secretion observed in vivo and in vitro in HNF-4<alpha>(loxP/loxP); Ins.Cre mice (see Discussion).

Prior studies using forced overexpression of either wild-type or a dominant negative version of HNF-4<alpha> in insulinoma cells had suggested a range of HNF-4<alpha> targets, many of them involved in glycolysis or mitochondrial function (10). Of these genes, only the gene encoding t-pyruvate kinase was differentially expressed in isolated islets of HNF-4<alpha> mutant mice (Figure 5C). Other important metabolic genes such as those encoding GLUT2, glucokinase, aldolase B, oxoglutarate dehydrogenase, and insulin, previously identified as putative HNF-4<alpha> targets, were not differentially expressed. The maintenance of normal expression of these genes is consistent with the unchanged ATP production in response to glucose in HNF-4<alpha>(loxP/loxP); Ins.Cre mice described above (Figure 4B).

Previous studies have suggested that HNF-4<alpha> may exert its function in the pancreatic beta cell through the regulation of HNF-1<alpha> expression (9, 10) and that the regulation of HNF-1<alpha> by HNF-4<alpha> is a component of a transcriptional regulatory loop that exists in the adult beta cell (11). However, using quantitative real-time PCR and Western blot analysis, we found that HNF-4<alpha> is not required for the maintenance of HNF-1<alpha> mRNA or protein expression in the adult beta cell (Figure 5, A and E). In addition to defining the mechanistic defect in HNF-4<alpha>(loxP/loxP); Ins.Cre mice. We treated islets with 0–30 mM glucose, which elicited a robust insulin secretory response in control islets (Figure 4A). In contrast, mutant islets lacked a first-phase secretory response to glucose. In addition, mutant islets failed to terminate insulin secretion when reexposed to buffer containing 0 mM glucose. Depolarization with KCl at the end of each experiment confirmed that the islets had remained viable throughout the experiment. HNF-4<alpha>-deficient beta cells exhibit a diminished response to glyburide. Glucose-stimulated insulin secretion from the pancreatic beta cell occurs after the generation of ATP from the metabolism of glucose through glycolysis and the Krebs cycle. The intracellular rise in the ATP/ADP ratio leads to the closure of the K<sub>ATP</sub> channels, calcium influx, and subsequent activation of insulin secretion through calcium-dependent pathways (24). This K<sub>ATP</sub>-dependent pathway is the best characterized mechanism leading to insulin secretion and is essential for proper first-phase insulin release.

We investigated whether components of this pathway were disrupted in HNF-4<alpha>(loxP/loxP); Ins.Cre mice by first measuring ATP levels in isolated islets stimulated with various concentrations of glucose. We found that at physiological glucose concentrations (2, 5, and 10 mM), ATP levels in HNF-4<alpha> deficient beta cells were indistinguishable from those of controls (Figure 4B), suggesting that glucose metabolism is maintained in mutant beta cells. To determine if calcium influx occurs properly in response to glucose, we performed calcium-imaging experiments using cultured isolated islets. In response to 16.7 mM glucose, intracellular calcium increased rapidly in control beta cells and then diminished when the addition of exogenous glucose was stopped (Figure 4C). However, intracellular calcium increased at a slower rate in mutant islets and failed to decrease as rapidly when glucose was stopped (Figure 4D). To determine if other insulin secretagogues can trigger proper calcium influx, we treated islets with the K<sub>ATP</sub> channel blocker glyburide as well as with KCl to fully depolarize the plasma membrane. In control islets, glyburide and KCl treatment resulted in a strong and rapid rise in intracellular calcium (Figure 4C). In contrast, intracellular calcium increased at a slower rate in mutant islets exposed to glyburide, but increased normally in response to KCl (Figure 4D).
tion, we did not find significant differences in mRNA levels of other MODY genes, including HNF-1β, Pdx-1, and NeuroD1, or those encoding other pancreatic transcription factors that regulate insulin secretion (Figure 5, A and B). Levels of mRNA in the gene encoding Foxa2, an essential regulator of Kir6.2 expression, were not altered significantly (18, 25). However, expression of the nuclear receptor HNF-4α was significantly reduced by approximately 34%, indicating that HNF-4α is required for normal expression of its related family member. Furthermore, PPARα, a target of HNF-4α in the liver (26) postulated to play a role in the β-oxidation of lipids in β cells (27), was downregulated by approximately 70% in mutant islets (Figure 5B).

HNF-4α binds the Kir6.2 promoter and activates the Kir6.2 gene in cotransfection assays. To evaluate whether HNF-4α can directly regulate Kir6.2 expression at the transcriptional level, we searched for potential HNF-4α binding sites in the Kir6.2 promoter. A putative HNF-4α binding site was identified 2,300 bp upstream of the transcriptional start site (Figure 6, A and B). In order to determine if HNF-4α can bind this sequence of the Kir6.2 promoter, we performed electrophoretic mobility shift assays (EMSAs). Incubation of wild-type liver nuclear extract with a radiolabeled oligonucleotide containing the putative HNF-4α binding site sequence resulted in a strong shift of the radioactive band (Figure 6C). The addition of an antibody against HNF-4α generated a supershifted band comparable to that achieved with the consensus site probe, but was not observed with preimmune serum, indicating that the bound protein was indeed HNF-4α. These results were also confirmed using an additional antibody against HNF-4α. To determine if the cis-regulatory element in the Kir6.2 gene can function as an HNF-4α-dependent enhancer, we performed cotransfection assays with a 237-bp region of the Kir6.2 gene containing the HNF-4α binding site cloned into a luciferase reporter plasmid and an HNF-4α expression vector. We found that overexpression of HNF-4α in baby hamster kidney (BHK) cells resulted in an increase of approximately 5-fold in luciferase activity and that this transcriptional activation was abolished when the HNF-4α binding site sequence was mutated (Figure 6D). Our results demonstrate that HNF-4α is a transcriptional activator of the Kir6.2 gene.

Discussion

MODY is a monogenic form of diabetes characterized by early onset and the progressive loss of insulin secretory capacity (28). Several recent reports have suggested that the MODY1 subtype results from the loss of HNF-4α function in the pancreas and that HNF-4α functions as “master regulator” of multiple transcriptional networks in the islet (11). However, the specific role for HNF-4α in the maintenance of β cell function has not to our knowledge been established until now. Here we have attempted to address this question by genetic means.

We used the Cre-loxP recombination system to delete HNF-4α in β cells of the adult pancreas. We found that 3- to 5-month-old HNF-4αcre/ loxP; Ins.Cre mice exhibited elevated plasma insulin levels in the fasted and fed states but also suffered from impaired glucose tolerance. Although these results provide evidence that HNF-4α is required in the β cell for the regulation of insulin secretion, the overall phenotype of these animals was quite surprising, considering the hypoinsulinemic hyperglycemia present in humans with reduced HNF-4α function. Given the relatively late onset of MODY1 in humans (15–25 years) compared with the age of our mice (3–5 months), and given that in MODY1 patients, HNF-4α function is impaired in the liver in addition to β cells, it appears likely that long-term and cumulative damage to the β cell contributes to the more severe phenotype observed in humans. However, consistent with the observations made in MODY1 patients, HNF-4αcre/ loxP; Ins.Cre mice failed to secrete adequate amounts of insulin after glucose stimulation and thus are glucose intolerant. This can be explained by our finding that isolated islets lacking HNF-4α demonstrated an abnormal response to glucose in perfusion experiments, including an attenuated first phase of insulin secretion.

Also surprising is the finding that HNF-1α, which is dependent on HNF-4α in hepatocytes (26), was not differentially expressed...
at the mRNA or protein level in HNF-4α mutant islets. Given the reports that HNF-4α binds to the HNF-1α promoter and that a mutation in the HNF-4α binding site on the HNF-1α promoter leads to MODY, one would expect HNF-4α to be an essential regulator of HNF-1α expression in the β cell (3, 11). However, as described by Servitja and colleagues, it is likely that the regulatory relationships between MODY genes vary between tissues and developmental stages (8). Although our results demonstrate that HNF-4α and PPARγ are not required for the maintenance of HNF-1α expression in adult β cells, it remains possible that HNF-4α is required for the initiation of HNF-1α expression earlier during pancreatic development. Another possibility is that the regulatory relationship is more important in the liver than in the β cell. However, the downregulation of HNF-4γ and PPARY suggests that HNF-4α functions in a transcriptional regulatory network involving other nuclear receptors.

Given the report by Wang and colleagues that HNF-4α expression is higher during pancreatic development. Another possibility is that the regulatory relationship is more important in the liver than in the β cell. However, the downregulation of HNF-4α and PPARYs suggests that HNF-4α functions in a transcriptional regulatory network involving other nuclear receptors.

Given the report by Wang and colleagues that HNF-4α expression is higher during pancreatic development. Another possibility is that the regulatory relationship is more important in the liver than in the β cell. However, the downregulation of HNF-4α and PPARY suggests that HNF-4α functions in a transcriptional regulatory network involving other nuclear receptors.

at the mRNA or protein level in HNF-4α mutant islets. Given the reports that HNF-4α binds to the HNF-1α promoter and that a mutation in the HNF-4α binding site on the HNF-1α promoter leads to MODY, one would expect HNF-4α to be an essential regulator of HNF-1α expression in the β cell (3, 11). However, as described by Servitja and colleagues, it is likely that the regulatory relationships between MODY genes vary between tissues and developmental stages (8). Although our results demonstrate that HNF-4α is not required for the maintenance of HNF-1α expression in adult β cells, it remains possible that HNF-4α is required for the initiation of HNF-1α expression earlier during pancreatic development. Another possibility is that the regulatory relationship is more important in the liver than in the β cell. However, the downregulation of HNF-4α and PPARY suggests that HNF-4α functions in a transcriptional regulatory network involving other nuclear receptors.

Given the report by Wang and colleagues that HNF-4α expression is higher during pancreatic development. Another possibility is that the regulatory relationship is more important in the liver than in the β cell. However, the downregulation of HNF-4α and PPARY suggests that HNF-4α functions in a transcriptional regulatory network involving other nuclear receptors.

Figure 5
Gene expression analysis in isolated islets of HNF-4αloxP/loxP; Ins.Cre mice. (A) Levels of mRNA of MODY genes, as determined by real-time PCR. (B) Levels of mRNA of pancreatic enriched transcription factors, as determined by real-time PCR. (C) Levels of mRNA of genes involved in glucose and lipid metabolism, as determined by real-time PCR. (D) Levels of mRNA of genes involved in stimulus-secretion coupling, as determined by real-time PCR. *P < 0.05; n = 3–5 for all PCR experiments. HPRT, hypoxanthine guanine phosphoribosyl transferase. (E) Western blot analysis of HNF-1α in isolated islets normalized to α-tubulin protein levels. C, control; M, mutant. (F) Western blot analysis of Kir6.2 in isolated islets normalized to α-tubulin protein levels. For all protein quantification, n = 3, controls, and n = 2, mutants.


1011
Using the HNF-4αloxP/loxP; Ins.Cre mouse model, we have revealed an unexpected role for HNF-4α in the regulation of the KATP channel–dependent pathway of glucose-stimulated insulin secretion. We have found that HNF-4α is required in the β cell for the maintenance of normal Kir6.2 mRNA and protein expression and that HNF-4α is a transcriptional activator of the Kir6.2 gene. Because Odom and colleagues examined only promoter elements located −700 bp to +200 bp relative to the transcriptional start site in their location analysis (11), they failed to identify target genes that are bound by HNF-4α further upstream, such as Kir6.2. The importance of Kir6.2 function in glucose homeostasis has been clearly established, because mutations in the Kir6.2 locus in humans can lead to persistent hyperinsulinemic hypoglycemia of infancy (32, 33). In addition, several mouse models have demonstrated the importance of the KATP channel in maintaining β cell function (34–38). In particular, expression of a dominant negative form of Kir6.2 leads to a reduction in or loss of KATP channel function and, consequently, elevated basal calcium levels and impaired glucose-stimulated insulin secretion from isolated islets (34, 36, 37). More recently, Li and colleagues used a hammerhead ribozyme to reduce Kir6.2 mRNA levels in RINm5F cells, resulting in a 60% decrease in KATP channel density, sufficient to diminish glucose-stimulated insulin release (38). In addition to the observed defects in glucose and sulfonylurea induced insulin secretion, another hallmark of KATP channel–deficient mice is the inability of isolated islets to properly shut off calcium influx and insulin secretion upon glucose withdrawal (39). The insulin secretory defects and calcium responses we have described here for HNF-4αloxP/loxP; Ins.Cre mice resemble many of the defects in KATP channel–deficient mice. It should be noted that because Kir6.2 levels are reduced but not absent in the HNF-4α mutants, the β cell defect in Kir6.2+/− mice is more severe than the defect in HNF-4α-deficient β cells. Nevertheless, Kir6.2−/− mice paradoxically exhibit an even more mild impairment in glucose tolerance. This is explained by the finding that Kir6.2−/− mice are hypersensitive to insulin due to the critical role of Kir6.2 in regulating glucose uptake by adipose tissue and skeletal muscle (36, 40). In HNF-4αloxP/loxP; Ins.Cre mice that we have derived here the expression of HNF-4α is lost only in the pancreatic β cells of the islet. Therefore, the skeletal muscle defects seen in Kir6.2−/− mice are not present in the HNF-4α mutants. This was confirmed by the normal insulin sensitivity of HNF-4αloxP/loxP; Ins.Cre mice (Figure 2G). However, transgenic mouse models of Kir6.2 have been reported in which a dominant negative form of Kir6.2 is expressed specifically in β cells (34, 37). Similar to HNF-4αloxP/loxP; Ins.Cre mice, Kir6.2-transgenic mice are hyperinsulinemic and exhibit defects in glucose-stimulated insulin secretion from isolated islets, including the loss of the first phase of insulin secretion, and abnormal calcium influx in response to glucose and sulfonylureas (34). Therefore, we propose that the maintenance of Kir6.2 expression by HNF-4α is necessary for normal glucose-stimulated insulin secretion and that the downregulation of Kir6.2 contributes in part to the observed phenotype of the HNF-4α mutant mice.

Although our data have shown that HNF-4α is required in the adult β cell for the regulation of insulin secretion, the absence of HNF-4α from the β cells of 5-month-old HNF-4αloxP/loxP; Ins.Cre mice is not sufficient to trigger the onset of overt diabetes. Several possibilities may explain this observation. First, the loss of HNF-4α from β cells of HNF-4αloxP/loxP; Ins.Cre mice may lead to hypergly-
cemia with increased age, in the presence of genetic modifiers, or in the presence of environmental factors such as a high-fat diet. The same factors have been shown to play a role in the eventual development of hyperglycemia observed in older Kir6.2-deficient mice. Older mice transgenic for a dominant negative mutant of Kir6.2 develop hyperglycemia and glucose intolerance (37). The progression to hyperglycemia is accelerated when these mice are fed a high-fat diet (41). Second, several mechanisms for nutrient-stimulated insulin secretion exist in the β cell. The mild impairment in glucose tolerance exhibited by KATP channel–deficient mice has been explained in part by the increased activity of KATP channel–independent pathways leading to insulin secretion (42, 43). Thus, while HNF-4α is essential for KATP channel–dependent insulin secretion, it is possible that other pathways that potentiate nutrient-stimulated insulin secretion can compensate in the short term to prevent more-severe impairments in glucose homeostasis. One possible alternate pathway is suggested by our finding that expression of the nuclear receptor PPARα was reduced in HNF-4α–deficient β cells. PPARα has been shown to activate genes encoding enzymes of the β-oxidation pathway of fatty acids. A decrease in β-oxidation is suggested to result in the accumulation of lipids in the cytoplasm, resulting ultimately in increased insulin secretion (44, 45). Given the postulated role of PPARα in the regulation of β cell lipid metabolism, it is possible that the lower level of PPARα in the HNF-4α mutants partially contributes to the elevated basal insulin levels (27). Third, as described above, it is possible that HNF-4α also plays an important role in the developing pancreas prior to excision of the floxed HNF-4α allele by the Ins.Cre transgene. Like many other pancreatic transcription factors such as Pdx-1 (MODY4) or Foxa2, HNF-4α may be required at multiple stages of pancreatic development. Finally, it is also likely that in mice and humans, contributions of other HNF-4α–deficient organs are necessary for the progression to type 2 diabetes. MODY 1 diabetics exhibit impairments in lipid homeostasis prior to the onset of hyperglycemia, indicating a primary hepatic lesion in these patients (46). Targeted disruption of HNF-4α in the adult liver also results in impaired lipid homeostasis, abnormal glycogen deposition, and hepatic hypertrophy (26). More recently, Parviz and colleagues have demonstrated the importance of HNF-4α in the formation of a hepatic epithelium during liver development (47). Thus, this raises the possibility that haploinsufficiency for HNF-4α in the liver also contributes to the progression of hyperglycemia in MODY1. Supporting this hypothesis are studies of MODY5. Patients with mutations in the MODY5 gene HNF-1β suffer diabetes and renal dysfunction (48). However, mice with a targeted deletion of HNF-1β in β cells are glucose intolerant due to impaired insulin secretion but do not exhibit hyperglycemia, providing another example of how the loss of a MODY gene only in the β cell may not be sufficient to trigger overt diabetes (49). Nevertheless, the model of HNF-1β and the model of HNF-4α reported in this article provide excellent tools to elucidate the mechanisms by which these MODY genes contribute to the maintenance of glucose homeostasis by the β cell.

In summary, our data provide genetic evidence that HNF-4α is required in the adult β cell for the regulation of β cell function. Our data also reveal an unexpected role for HNF-4α in the regulation of the KATP channel–dependent pathway of insulin secretion. The model derived here will serve as a useful tool for identifying additional genes and pathways dependent on HNF-4α activity and may lead to novel treatment regimens for type 2 diabetes.

**Methods**

**Animals and genotype analysis.** The derivation of both HNF-4αloxP/loxP and Ins.Cre mice has been reported previously (15, 50). All mice were maintained on the CD1 background. Genotyping was performed by PCR analysis using genomic DNA isolated from the tail tips of newborn mice. All of the experiments described here focused on female mice, because female HNF-4αloxP/loxP, Ins.Cre mice showed larger impairments in glucose homeostasis compared with age- and sex-matched control mice on a standard diet than did male mice (Figure 2). Littermate HNF-4αloxP/loxP and HNF-4αloxP/loxP female mice were used as controls. All procedures involving mice were approved by the University of Pennsylvania Institutional Animal Care and Use Committee.

**Immunofluorescence and immunohistochemistry.** Indirect immunofluorescence was performed as described previously (18) and was examined using confocal microscopy (Leica Microsystems Inc.). The following antibodies were used: guinea pig anti-insulin (1:800 dilution; Linco Research Inc.), rabbit anti-glucagon (undiluted; Zymed Laboratories Inc.), rabbit anti-somatostatin (1:50 dilution; Zymed Laboratories Inc.), indecarboxyamine-conjugated donkey anti-rabbit IgG (1:750 dilution; Jackson ImmunoResearch Laboratories Inc.), and carboxyamine-conjugated donkey anti-guinea pig IgG (1:200 dilution; Jackson ImmunoResearch Laboratories Inc.).

For immunohistochemistry, slides were blocked with avidin D and biotin blocking reagents (Vector Laboratories) for 15 minutes at room temperature. Anti-HNF-4α (SC-6556; Santa Cruz Biotechnology) was diluted in phosphate buffered saline plus tween (PBST) and was incubated with tissue overnight at 4°C. Slides were washed in PBS and were incubated with biotinylated anti-goat. HRP-conjugated avidin–biotinylated enzyme complex reagent was used following the manufacturer’s protocol (Vector Laboratories). Signals were developed using 3,3-diaminobenzidine tetrahydrochloride as substrate. For β cell mass determination, pancreata were laid flat during the paraffin-embedding process. The section with the largest tissue surface area was stained for insulin by immunohistochemistry as outlined above. Quantification of β cell mass was performed as described previously (16).

**Glucose and insulin tolerance tests.** For glucose tolerance tests, animals that had fasted overnight (16 hours) were injected intraperitoneally with 2 grams of glucose (Sigma-Aldrich) per kilogram of body weight. Glucose levels were measured at 0, 15, 30, 60, 90, and 120 minutes with Glucometer Elite (Bayer Corporation). For determination of plasma insulin concentrations during glucose tolerance tests, animals that had fasted overnight were injected with 3 grams of glucose per kilogram of body weight and blood was collected from the tail vein at 0, 2, 5, 15, and 30 minutes after injection. Plasma insulin measurements were performed by ELISA (Crystal Chem Inc.) For insulin tolerance tests, mice that had fasted for 4 hours were injected intraperitoneally with 0.75 units of insulin per kilogram of body weight. Glucose levels were measured at 0, 15, 30, 60, 90, and 120 minutes as described above.

**Islet perfusions.** For each experiment, 100 islets were isolated from 3- to 5-month-old mutants and controls using standard collagenase digestion followed by purification through a Ficoll gradient (51). One hundred islets were “hand-picked” under a light microscope and were placed into a perfusion chamber (Millipore). A computer-controlled fast-performance HPLC system (625 LC System; Waters Corporation) allowed for programmable rates of flow and concentration of the appropriate solutions held at 37°C in a water bath. Islets were perfused with Krebs bicarbonate buffer (2.2 mM Ca²⁺, 0.25% bovine serum albumin, 10 mM HEPES [acid], and 95% O₂ and 5% CO₂ equilibration, pH 7.4) to reach baseline hormone secretion values before the addition of the appropriate secretagogues. Samples were
research article

collected at regular intervals with a fraction collector (Waters Corporation) and insulin content was determined using a radioimmune assay (University of Pennsylvania Diabetes Center).

**ATP assays.** Isolated islets were cultured at 37°C and 5% CO₂ for 3 days in RPMI 1640 medium (glucose-free; Sigma-Aldrich) supplemented with 10% FBS, 2 mM glutamine, 100 units/ml penicillin, 50 μg/ml streptomycin, and 10 mM glucose. Then, 50 islets per condition were preincubated for 90 minutes at 37°C and 5% CO₂ in glucose-free Krebs bicarbonate buffer and then were incubated for 60 minutes in buffer containing the indicated amounts of glucose (Figure 4B). ATP was extracted from islets as described previously (52).

**Calcium imaging.** Isolated islets were cultured for 3 days in 10 mM glucose and were pretreated at 37°C for 40 minutes in Krebs bicarbonate buffer supplemented with 1 mM fura-2 acetoxyxymethylster (fura-2AM; Invitrogen Corp.). The fura-2AM–loaded islets were transferred to a perfusion chamber and were placed on the homeothermic platform of an inverted Zeiss microscope for visualization with a 40× oil-immersion objective (Carl Zeiss MicroImaging Inc.). Islets were perfused with Krebs bicarbonate buffer at 37°C at a flow rate of 2 ml/min while various treatments were applied. The intracellular calcium concentration was determined by the ratio of the excitation of fura-2-AM at 334 nm to that at 380 nm. Emission was measured at 520 nm with an Attofluor charge-coupled device camera and was calibrated using Attofluor Ratio Vision Software (BD Biosciences). The rate of change in intracellular calcium was calculated from the first 6 data points starting with the data point prior to the first observed increase in calcium.

**Real-time PCR and Western blot analysis.** Islets from 3- to 5-month-old mice were isolated using the standard collagenase procedure as described above. Total RNA from islets was isolated in Trizol (Invitrogen Corp.) according to the manufacturer's instructions. Islet RNA was reverse-transcribed using 1 μg oligo(dT) primer, Superscript II Reverse Transcriptase, and accompanying reagents (Invitrogen Corp.). PCR reaction mixes were assembled using the Brilliant SYBR Green QPCR Master Mix (Stratagene). Reactions were performed using the SYBR Green (with Dissociation Curve) program on the MX4000 Multiplex Quantitative PCR System (Stratagene). All reactions were performed in triplicate with reference dye normalization, and median cycling threshold values were used for analysis. Primer sequences are available upon request. Islet purity was assessed as previously described (25). For Western blots, islet extracts were prepared as described previously (53), were separated by SDS-PAGE, were transferred to immobilon P membranes (Millipore), and were probed with rabbit polyclonal anti-Kir6.2 (Chemicon International Inc.), rabbit anti–HNF-1α (Santa Cruz Biotechnology Inc.), and monoclonal anti–α-tubulin (Sigma-Aldrich). The ECL Plus detection system was used to detect the signal (Amersham Pharmacia). Band intensities were quantified using the QuantityOne 4.3.1 program (Biorad Laboratories). Intensities were normalized to those obtained for α-tubulin.

**Computational identification of HNF-4α binding sites in the Kir6.2 promoter.** For the identification of potential HNF-4α binding sites in the Kir6.2 promoter, 4.5 kilobases of promoter sequence upstream of the transcriptional start site was retrieved from the University of California Santa Cruz Genome Browser (http://www.genome.ucsc.edu) and was uploaded into the NUBIScan website (http://www.nubiscan.unibas.ch), which uses an in silico approach for predicting nuclear receptor response elements (54). A directed search for DR1 (direct repeat with single nucleotide spacing) half-sites using the HNF-4α site in the Kir6.2 gene were as follows: forward, 5′-GGGGAAAGGCGACAAAAGGGGCAGACCCT-3′; reverse, 5′-GGGGAGGTCTCGCCCTTTGGTGCTGCGCTT-3′.

**Transient transfections and luciferase reporter assays.** A 237-bp fragment of the Kir6.2 promoter containing the putative HNF-4α binding site was cloned by PCR to contain KpnI and BglII restriction enzyme sites on the 5′ and 3′ ends, respectively. A mutated version of this element was generated by overlap PCR (Figure 6D). The wild-type and mutant PCR fragments were then cloned into the KpnI and BglII sites of the pGL3 promoter luciferase vector (Promega Corp.). The pCMV-β-HNF-4α plasmid (a kind gift from M. Stoffel, Rockefeller University, New York, New York, USA) was used to express FLAG-tagged HNF-4α under control of the cytomegalovirus promoter. BHK cells (5 × 10⁴) were seeded 16 hours prior to transfection in 60-mm dishes and were cultured in DMEM supplemented with 10% FBS, 1-glutamine, penicillin, and streptomycin. Transient transfections were performed using the Effectene transfection reagent (Qiagen) according to the manufacturer’s instructions. At 24 hours after transfection, cells were harvested and luciferase activity was measured using the Dual Luciferase Reporter Assay (Promega Corp.). Luciferase activity was normalized for transfection efficiency by the corresponding Renilla luciferase activity.

**Acknowledgments**

The authors are grateful to M.A. Lazar, D.A. Stoffers, and J.R. Friedman for critical reading of the manuscript. The authors thank Kristen A. Lantz, Sara D. Sackett, Regina K. Gorski, Maria Golson, John E. Brestelli, and Peter White for contributions to this work, and Shamina Rangwala and Phillip P. Le for valuable discussions. The authors are also grateful to Heather Collins for performing radioimmune assays, Nicolai Doliba for help with calcium-imaging experiments, and Harshani Peiris and Linda Greenbaum for liver nuclear extracts. Our studies were assisted by the University of Pennsylvania Diabetes Center (P30DK50306). This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grants DK55743 and DK60064 to S.A. Friedman, John E. Brestelli, and Peter White for contributions to this work, and Shamina Rangwala and Phillip P. Le for valuable discussions. The authors are also grateful to Heather Collins for performing radioimmune assays, Nicolai Doliba for help with calcium-imaging experiments, and Harshani Peiris and Linda Greenbaum for liver nuclear extracts. Our studies were assisted by the University of Pennsylvania Diabetes Center (P30DK50306). This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grants DK55342 and DK56947 to K.H. Kaestner; DK55743 and DK60064 to S.A. Duncan; and DK61226 to C.S. Lee).

Received for publication June 7, 2004, and accepted in revised form January 18, 2005.

**Address correspondence to:** Klaus H. Kaestner, Department of Genetics, University of Pennsylvania School of Medicine, 415 Curie Boulevard, Philadelphia, Pennsylvania 19104-6145, USA. Phone: (215) 898-8759; Fax: (215) 573-5892; E-mail:kaestner@mail.med.upenn.edu.


